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ABSTRACT
Wnt-induced secreted protein 1 (WISP-1/CCN4) is a member of the CCN family that is highly expressed in skeletal tissue and in
osteoprogenitor cellsinducedtodifferentiateinvitro.TodeterminethefunctionofWISP-1during osteogeneis,osteogenic bonemarrow
stromal cells (BMSCs) were transduced with WISP-1 adenovirus (adWISP-1) in the presence or absence of bone morphogenetic protein 2
(BMP-2) adenovirus (adBMP-2). WISP-1 overexpression enhanced the ability of BMP-2 to direct BMSCs toward osteogenic differentiation
and appeared to work by stimulating Smad-1/5/8 phosphorylation and activation. The ability of WISP-1 to enhance BMP-2 activity also
was shown in vivo using an ectopic osteogenesis assay with BMSCs transduced with WISP-1, BMP-2, or both. When BMSCs were infected
withlentiviruscontaininghumanWISP1shRNA, theyformedless boneinvivoandwerelessresponsivetoBMP-2,confirming thatWISP-1
andBMP-2haveafunctionalinteraction. Immunoprecipitation (IP)andWestern blotanalysis showedthat WISP-1bound directlytoBMP-
2andshowedthatWISP-1increasedBMP-2bindingtohBMSCsinadose-dependentfashion.TounderstandhowWISP-1enhancedBMP-
2signaling,theinfluenceofWISP-1onintegrinexpressionwasanalyzed.WISP-1inducedthemRNAandproteinlevelsofa5-integrinand,
further, was found to bind to it. Antibody-blocking experiments showed that the BMP-2 binding to BMSCs that was enhanced by WISP-1
was completely neutralized by treatment with anti-integrin a5b1 antibody. Pilot studies and the use of transgenic mice that
overexpressed human WISP-1 in preosteoblasts had increased bone mineral density (BMD), trabecular thickness, and bone volume
(BV/TV) over wild-type controls, supporting observations using human osteoprogenitors that WISP-1 has a positive influence on
osteogenesis in vivo. In conclusion, these studies show, for the first time, that WISP-1 has a positive influence on bone cell differentiation
and function and may work by enhancing the effects of BMP-2 to increase osteogenesis through a mechanism potentially involving
binding to integrin a5b1.  2011 American Society for Bone and Mineral Research.
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Introduction
W
ithanagingworldpopulation,thesearchformoreefficient
drugtargetsforage-relateddisorders suchasosteoporosis
and osteoarthritis has become essential. The use of antiresorp-
tive drugs has prevailed as the most common treatment of
osteoporosis. However, in more recent years, the use of anabolic
agents such as parathyroid hormone (PTH) and bone morpho-
genetic protein 2 (BMP-2) has become more common. Most
recently, the search for biologic proteins that can increase
bone mass has focused on the Wnt signaling pathway owing to
reports of high bone mass in people with mutations in the Wnt
receptor LRP5/6. Wnt-induced secreted protein 1 (WISP-1/CCN4)
is a member of the CCN family that is highly expressed in skeletal
tissues. Evidence points to a role for WISP-1 in bone formation
andmaintenance.ExpressionofWISP-1hasbeenobservedinthe
developing skeleton and later in both preosteoblastic and
osteoblastic cells,
(1) specifically at sites of new bone formation
during development or in healing fracture calluses.
(2) WISP1 was
identified initially as the principle target gene of the Wnt-1/
Frizzled pathway in breast cancer cells, with its expression
regulated by b-catenin.
(3) The Wnt/b-catenin signaling pathway
has proved to be essential in the regulation and maintenance of
bone mass,
(4,5) and mutations in LRP5/6 that prevent binding to
its inhibitor, dickkoff 1, cause high-bone-mass phenotype in
humans.
(6–8) Moreover, WISP1 has been identified as a gene
that is highly upregulated in osteoarthritis.
(9,10) Previous work
from our lab has shown that recombinant WISP-1 promotes the
proliferation and differentiation of human bone marrow stromal
cells (hBMSCs) in vitro via a relationship with members of the
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193transforming growth factor b (TGF-b) superfamily.
(11) However,
the exact skeletal functions of WISP-1 in vivo or the molecular
mechanism involved have not yet been elucidated.
The CCN family consists of its three founding members,
Cyr61 (CCN1/Cyr61/Cef10), connective tissue growth factor/
CTGF (CCN2/CTGF/Fisp12), and Nov (CCN3/Nov)
(12,13) and the
later identified WISP-1 (CCN4/rCOP-1/Elm-1), WISP-2 (CCN5), and
WISP-3 (CCN6). CCN family proteins are characterized by four
distinct functional domains: (1) an insulin-like growth factor–
binding protein–like module (IGFBP), (2) a von Willebrand factor
type C repeat (VWC), (3) a thrombospondin type 1 repeat (TSP1),
and (4) a cysteine-rich C-terminal module (CT). CCN5 is the
exception, being a trimodular protein lacking the CT module.
Numerous studies have demonstrated a role for the CCN family
members in the regulation the osteo/chondrogenic differentia-
tion of musculoskeletal cells both in vitro and in vivo.
(12,14–19)
In addition, the CCN family has been implicated in the pathology
of a number of fibrotic disorders
(20) and several types of
malignancies, including breast,
(21,22) prostate,
(23–25) and gastric
cancers,
(26,27) and have functions identified in numerous biologic
processes such as embryonic development, angiogenesis, cell
differentiation, and tissue repair (for a recent review see refs.
(2),
(12),
(17),
(28), and
(29)). At the cellular level, CCN proteins can
act as growth factors to stimulate differentiation and collagen
synthesis
(13,30) or to mediate cell binding, migration, and
signaling via interactions with integrins.
(31–38) In addition, CCN
family members also have been identified as factors that can
regulate members of the TGF-b superfamily.
(39–41)
Bone morphogenetic proteins (BMPs) are members of the
TGF-b superfamily of polypeptides.
(42,43) A fundamental function
of BMPs is to induce the differentiation of mesenchymal
osteoprogenitors toward cells of the osteoblastic lineage and
then to promote osteoblastic maturation and function. This
cellular regulation, in turn, can control the development of bone
and cartilage and the accelerated healing of fractured bones.
While BMPs play essential roles in bone formation and
remodeling, there is still a need to modulate their activities.
(42,43)
Numerous antagonists of BMPs exist, such as noggin, chordin,
short gastrulation (Sog), and twisted gastrulation (Tsg),
(42,43) that
control BMP activity. The modulation of BMP activity also can be
achieved by local feedback mechanisms, involving growth
factor–binding proteins and other intracellular factors. Indeed,
the CCN proteins CCN2/CTGF and CCN3/Nov both bind to BMPs
and temper their functions in vitro and in vivo.
(15,16) These
studies suggest that the CCN family is involved in regulation of
osteoblast differentiation by interacting with members of the
TGF-bfamilysuchasBMP-2,agrowthfactorlongknowntobean
important modulator of skeletogenesis.
(44) We have shown
previously a cooperative relationship between WISP-1 and
TGF-b in regulating osteoblastic proliferation and differentiation.
However, the relationship of WISP-1 to BMP-2 in bone formation
has not yet been determined.
To deepen our understanding of the function of WISP-1 in
osteogenesis, we investigated the effect of WISP-1 on BMP-2-
induced osteogenic differentiation and found that WISP-1
potentiates the effects of BMP-2 in progenitor cells from the
bone marrow. The importance of WISP-1 in enhancing BMP-2
function in vivo was determined using an ectopic osteogenesis
assay. Evidence points to an essential role of CCN family
members in integrin binding and signaling; therefore, we also
determined the effects of WISP-1 on integrin production and
function and found a functional relationship between WISP-1
and a5b1 integrin that can regulate BMP-2 bioavailability
in hBSMC cultures. Taken together, these data present a new
paradigm revealing that WISP-1 has enhancing effects on BMP
function during osteogenesis that are potentially dependent on
the integrin a5b1.
Materials and Methods
Cells and culture medium
Human BMSCs (hBMSCs) were isolated using methods reported
previously.
(11) All specimens were used in accordance with the
NIH regulations governing the use of human subjects under
Institutional Review Board (IRB) exemption (D-0188). hBMSC
cultures were maintained in a-minimal essential medium
(a-MEM, Invitrogen, Carlsbad, CA, USA) containing 20% fetal
bovine serum (FBS), 2mM glutamine, 100U/mL of penicillin, and
100mg/mL of streptomycin sulfate (Invitrogen). In all experi-
ments, hBMSCs were used between the third and seventh
passage. To induce cells toward an osteoblast-like phenotype,
cultures were supplemented with 100mg/mL of L-ascorbic acid
(Wako, TX, USA), 1.8mM of KH2PO4, and 10nM of dexametha-
sone (Sigma, St Louis, MO, USA). Mouse BMSCs (mBMSCs) were
isolated as described previously
(45) and cultured in a-MEM
containing 20% lot-selected FBS, 2mM of glutamine, 100U/mL
of penicillin, 100mg/mL of streptomycin sulfate, 10nM of
dexamethasone, and 55mM of 2-mercaptoethanol (Invitrogen).
The osteogenesis-inducing medium was supplemented with
100mM of ascorbic acid 2-phosphate and 2mM of b-
glycerophosphate (Sigma).
(11)
C2C12 mouse myoblast cells, which have a stably integrated
reporter plasmid consisting of the BMP-responsive element from
the Id promoter fused to a luciferase reporter,
(46) were kindly
supplied by Drs L Zilberberg and D Rifkin (New York University
School of Medicine, New York, NY, USA). C2C12 cells were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM)
containing 10% FBS, 100U/mL of penicillin, and 100mg/mL of
streptomycin sulfate.
Generation and transduction of adenovirus
Adenoviruses encoding human WISP-1 were generated using
the BamHI/NotI fragment of full-length human WISP1 cDNA,
(11,47)
clonedintotheadenovirusvectorVQad5DMVK-NpA(Viraquest,
North Liberty, IA, USA). The resulting plasmid, named adWISP-1,
was subject to homologous recombination, and the large-scale
amplification of purified plaques was carried out by Viraquest.
AdenovirusencodingmurineBMP(adBMP-2)
(48)wasthekindgift
of Dr R Francheschi (University of Michigan, Ann Arbor, MI, USA)
and was amplified and purified by Viraquest. For transduction of
adenovirus, the cells were first grown to 80% confluency and
thenincubatedwithmediumcontaininganadenovirus(hBMSCs:
5 10
3 particles/cell; C2C12 cells: 1 10
3 particles/cell). Optimal
viral doses for transduction of hBMSCs or C2C12 cells were
determined by serial plaque-forming unit (PFU) dilution and
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time PCR (not shown). Cells were used 72hours after transduc-
tion unless otherwise specified.
Lentivirus production and transduction
Lentiviral constructs carrying shRNA targeting human WISP1
mRNA were purchased from OpenBioSystems (Huntsville, AL,
USA). The pLKO.1 gene set for WISP1 contained five different
clones: AXA20-B10, AAE91-A-7, AAE91-A-8, AAE-91-9, and
AAE91-A10. The plasmid pLKO.1 eGFP lentivirus was used as a
control(GFP).PlasmidDNAwasamplifiedandpurifiedusingCsCl
gradients and then transfected along with packaging plasmids
into HEK293T cells to generate VSV-g pseudotyped lentivirus
particles. The cells wererefed with DMEM medium, 10%FBS, and
1% Penn-Strep for 24hours after transfection, and the culture
supernatant was harvested 48hours after transfection. The
supernatants containing infective lentivirus were clarified by
centrifugation and filtration and used to infect hBMSC culture
using the same culture procedures described earlier except that
2mg/mL of puromycin was added to select cells with integrated
DNA. After antibiotic selection for 2 days, cells were analyzed for
relative production of WISP1 mRNA using real-time PCR, and the
c l o n ew i t ht h eg r e a t e s tr e d u c t i o ni nr e l a t i v ee x p r e s s i o no fWISP1
wasusedforinvitrodifferentiationandinvivoosteogenesisassays.
In vivo osteogenesis assay
Fortheinvivoosteogenicectopicassay3 10
6shRNAlentivirus-
or GFP control virus-infected hBMSCs were mixed with 40mg of
hydroxyapatite/tricalcium phosphate powder (Warsaw, IN, USA)
and implanted under the skin on the backs of 8-week-old
athymicnude mice (Harlan, Madison, WI, USA). After 6weeks, the
transplants were harvested and fixed and embedded in paraffin,
serial 6-mm sections were stained with hematoxylin and eosin,
and quantification of de novo bone formation was performed
using a BZ-8000 microscope equipped with a BZ analyzer
(Keyence, Osaka, Japan). Specifically, three separate areas of the
implant was traced and then tabulated using the BZ software,
which determined the percent bone area/total area. The same
procedure was used for the gain-of-function experiments except
that hBMSCs were transduced with adenovirus as described
earlier and harvested at 4 weeks instead of 6 weeks.
Reverse-transcriptase polymerase chain reaction (RT-PCR)
and real-time RT-PCR analysis
Total cellular RNA was extracted using RNeasy (Qiagen,
Gaithersburg, MD, USA) according to the manufacturer’s
protocol and cDNA produced by reverse transcription of RNA
using the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA).
PCR amplification of cDNA was carried out using GoTaq Green
Master Mix (Promega, Madison, WI, USA) employing gene-
specific primer sets (listed in Table 1). Primers were designed
using Beacon Software from Bio-Rad with parameters set for use
with real-time PCR and for a Tm of 628C 38C with an amplicon
size of 75 to200 bp(Table 1). Real-timeRT-PCR was performed to
quantify the expression of mRNA using a MyiQ (Bio-Rad) with iQ
SYBR Green Supermix (Bio-Rad). For each primer set, melting
curves were performed to ensure that a single peak was
produced, and the products were analyzed by gel electrophor-
esis. All real-time PCR reactions were normalized to the levels of
ribosomal protein S29 (s29) mRNA for real-time PCR or to the
levels of Gapdh for semiquantitative RT-PCR.
In vitro calcium accumulation
Calcium deposits were detected by staining with 2% alizarin red
S (pH 4.2, Sigma) and quantified by elution of bound alizarin red
with 0.5mL of 5% SDS in 0.5N HCl for 30 minutes at room
temperature and measuring the absorbance at 405nm.
Solid-phase binding assay
Polystyrene microtiter plates were coated with bait proteins
prepared in a 0.1% BSA/PBS solution by overnight incubation at
48C. Unbound protein was removed, and nonspecific binding
sites were blocked with 1% BSA in PBS for 1 hour at room
temperature. Bait-coated plates were incubated with test
proteins prepared in 1% BSA/PBS solution for 2hours at room
temperature. Following washes with 1% BSA/PBS solution,
protein binding was assayed by incubating with primary
antibody to the proteins being tested for 1 hour, after which
the wells were washed and incubated for 1 hour with goat
antirabbit horseradish peroxidase (HRP) conjugate (Pierce,
ThermoScientific,Rockford,IL,USA).Attheendoftheincubation
period, the wells were washed six times with PBS containing
0.05% Tween 20 before visualization of signal using an HRP
chromogenic substrate (TMB, Kirkegaard & Perry Laboratories,
Gaithersburg, MD, USA). The reaction was stopped with 1M
phosphoric acid, and the absorbance at 450nm was measured.
Nonspecific binding was determined in parallel incubations by
omitting microtiter well coating.
Immunoprecipitation
Cells were harvested using NP-40 buffer (1% NP-40, 0.15M NaCl,
0.01M sodium phosphate, and 1mM EDTA) containing a
Complete Protease Inhibitor Mixture (Roche Diagnostics,
Mannheim, Germany). Cleared cell lysates were incubated with
anti-BMP-2 (sc-6895, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) or anti-integrin a5b1 (Millipore, Bellierica, MA, USA)
antibodies that were bound to Dynabeads protein G (Dynal,
Invitrogen). The beads were washed extensively, and bound
proteins were boiled in loading buffer for 5minutes and
separated by SDS-PAGE and analyzed by immunoblot with anti-
WISP-1 antibody (LF-187). Details on the construction and
specificity of LF-187 have been described previously.
(49)
Western blot analysis
Total cellular proteins were prepared by lysing cells in M-PER
mammalian protein extraction reagent (Pierce) or PhosphoSafe
Extraction Reagent (Novagen, Darmstadt, Germany) supplemen-
ted with a protease inhibitor cocktail (1mg/mL; Roche,
Indianapolis, IN, USA). Following centrifugation at 10,000rpm
for 20 minutes at 48C to remove cell debris, the protein content
of the cell lysate was determined using a BCA assay kit (Pierce).
Between 1 and 30mg of total protein was separated by
electrophoresis on 4% to 12% Bis-Tris precast polyacrylamide
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thentransferredontopolyvinylidenefluoride(PVDF)membranes
(Immobilom-FL, Millipore) at 100V for 2hours with cooling. Blots
were blocked with Odyssey Blocking Buffer (Licor, Lincoln, NE,
USA) for 1 hour at room temperature before overnight
incubation at 48C with primary antibodies to WISP-1 (LF-187
1:1000), pSmad-1/5/8 and total Smad-1 (1:1000; Cell Signaling
Technologies, Danvers, MA, USA), and bCBFA1/AML3 (1:100;
Calbiochem, La Jolla, CA, USA). Membranes were probed with
fluorescently labeled secondary antibody (1:10,000; Licor), again
diluted in blocking solution and incubated for 1 hour at room
temperature. After washing with Tris-buffered saline with Tween
(TBS-T), membranes were scanned with an Odyssey scanner
(Licor). Blots were stripped of antibodies using OneMinute
Western Blot Stripping Buffer (GM Biosciences, Inc., Frederick,
MD, USA) and reprobed to determine relative loading efficiency
using antibodies to HSP-90 (1:2000; Santa Cruz Biotechnology),
or b-actin (1:10,000; Sigma).
BMP-responsive luciferase reporter assay
Stably transfected C2C12 cells expressing the BMP-responsive
mouseIdpromoterwereusedtoassayBMPactivity.BRE-lucC2C12
cells (4 10
3 cells/well) were plated into white clear-bottomed 96-
well plates. After 24hours, cells were infected with adWISP-1,
adBMP-2, or both (multiplicity of infection [MOI]: 1000 PFU). Then
72hours after infection, a Steady-Glo Reagent (Promega) was
added in each well, and luciferase activity was measured using a
microplate luminometer (Berthold, Wildbad, Germany).
‘‘On cell’’ binding
To analyze the effect of a5b1 intergrin on WISP-1-induced BMP-2
binding, human BMSCs were seeded at 1 10
4 cells/well in 96-
well plates and preincubated with 10mg/mL of anti-a5b1
integrin antibody (Millipore) or IgG control for 1 hour and then
transduced with adWISP-1. After 2 days, the cells were fixed for
60minutes in 4% phosphate-buffered formaldehyde at room
temperature, washed with PBS, and blocked in Odyssey Blocking
Buffer (Licor) for 1 hour at room temperature. The affinity of
BMP-2 to bind to hBMSCs in response to WISP-1 overexpression
then was tested by incubating with BMP-2 (10mg/mL; R&D,
Minneapolis, MN, USA) for 2hours at room temperature. Cells
treated without BMP-2 were used to distinguish endogenous
BMP-2 and served as negative controls. Bound BMP-2 was
identified by incubation of anti-BMP-2 antibody (2.5mg/mL;
Santa Cruz Biotechnology) for 1 hour and fluorescently labeled
secondary antibody (1:200; Licor) for 1 hour at room tempera-
ture.Todetectlevelsofcellsurface–associatedWISP-1,cellswere
incubated with WISP-1 antibody (LF-187, 1:200) for 1 hour and
then washed and incubated with fluorescently labeled second-
ary antibody (1:200; Licor) for 1 hour at room temperature. The
relative levels of fluorescently bound secondary antibody were
measured using an Odyssey scanner (Licor).
Generation of transgenic mice overexpressing
human WISP1
A plasmid containing a full-length human WISP1 cDNA was the
kind gift of Arnold Levine (Rockefeller University, New York, NY,
Table 1. Primers Used for RT-PCR and Real Time RT-PCR Experiments
Gene GenBank accession no. Primer sequence PCR product length (bp)
Gapdh
a,c BC082592 5’-GAGAGGCCCTATCCCAACTC-3’ (S) 148
5’-GTGGGTGCAGCAGCGAACTTAT-3’ (AS)
Wisp-1
a,c BC048791 5’-TGGCAGCAGTGACAGCAGCA-3’ (S) 355
5’-GACCTGTGACCTTTAGGTGTGA-3’ (AS)
WISP-1
b,d AF100779 5’-TGGCAGCAGTGACAGCAGCA-3’ (S) 609
5’-TACGGAGGTGGAGTGGGTGT-3’ (AS)
S29
b,d BC032813 5’-TCTCGCTCTTGTCGTGTCTGTTC-3’ (S) 75
5’-ACACTGGCGGCACATATTGAGG-3’ (AS)
ALP
b,d NM_000478 5’-GCACCGCCACCGCCTACC-3’ (S) 150
5’-CCACAGATTTCCCAGCGTCCTTG-3’ (AS)
OPN
b,d NM_000582 5’-CTGTGTTGGTGGAGGATGTCTGC-3’ (S) 143
5’-GTCGGCGTTTGGCTGAGAAGG-3’ (AS)
WISP-1
b,d AB034725 5’-ACACTCATTAAGGCAGGGAAGAAG-3’ (S) 185
5’-TCAGGACACTGGAAGGACACG-3’ (AS)
Integrina5
b,d NM_002205 5’-GGGCTGGATGACTTGCTGGTG-3’ (S) 125
5’-GTGGGCGTGGGCTCTATGC-3’ (AS)
Integrinav
b,d BC047454 5’-AGCGGGACCATCTCATCACTAAGC-3’ (S) 86
5’-CAAGCACTGAGCAACTCCACAACC-3’ (AS)
Integrinb1
b,d BC020057 5’-TGGGCTTTACGGAGGAAGTAGAGG-3’ (S) 90
5’-GACACTTGGGACTTTCAGGGATGC-3’ (AS)
Integrinb3
b,d NM_000212 5’-TAGAAGAGCCAGAGTGTCCCAAGG-3’ (S) 128
5’-TCGGTCGTGGATGGTGATGAGG-3’ (AS)
S, sense; AS, antisense.
amouse;
bhuman;
cRT-PCR;
dreal time RT-PCR.
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retroviralDNAvectorandsubclonedintopcDNA3.1–(Invitrogen)
using BamHI and EcoRI sites. Large-scale synthesis and
purification of endotoxin-free plasmids were carried out using
standardtechniquesandtheQiagenEndo-FreeMaxiPreparation
Purification Kit, and the integrity of the construct was confirmed
by DNA sequencing. The Col1A1 promoter ( 2310 to þ110) was
the kind gift of Benoit deCrombrugge (MD Anderson Cancer
Center, Houston, TX, USA). Following release from the pJ251
using Asp718 and BamH1 sites, the promoter was cloned
immediately upstream of WISP1 in pcDNA3.1– to produce a final
construct of 9.12kb (Col1A1-WISP1 pcDNA). Transgenic mice that
express WISP1 under control of the Col1A1 promoter were
generated using a 4.8-kb DNA fragment including the Col1A1
promoter (2.3kb of promoter, 0.1kb of exon 1), WISP-1 (1.3kb),
and the bovine growth hormone polyA tail (BGH pA) (1.1kb),
which was excised from Col1A1-WISP1 pcDNA using ASP718 and
StuI and purified by sucrose gradient. Transgenic mice were
prepared by pronuclear injection with assistance from the
NIDCR-DIR Functional Genomics Core Facility. Six founder mice
were identified that contained the transgene, as judged by
SouthernblotanalysisofDNAisolatedfrommousetailsusingthe
4.8-kb fragment generated for pronuclear injection as the probe.
Two of the founder lines showed high levels of transgene
integration. One mouse line that overexpressed the transgene,
as detected by Western blot analysis of mouse bone, was
identified and was studied in greater detail subsequently. A PCR
strategy was devised for routine genotyping using primers in the
3’ end of the col1A1 promoter (5’-TGGACTCCTTTCCCTTCCTT-3’)
and the 5’ end of the human WISP1 cDNA (5’-GCAGGAAC-
CACCTCATGC-3’).
X-ray and micro–computed tomographic (mCT) analysis
Femurs were dissected from wild-type and WISP1 transgenic
mice and subject to radiography using Kodak X-OMAT TL film
(Rochester, NY, USA) and a Model FX-20 Faxitron X-ray system
(Lincolnshire, IL, USA) at a setting 30kV using a 40-second
exposuretime. Thefemurs werescannedand reconstructed with
8-mm isotropic voxels on a mCT analysis system (eXplore MS, GE
Medical Systems, London, Ontario, Canada). A bone standard
(SB3, Gammex RMI, Middleton, WI, USA) was scanned with the
mCT and used for the calibration of bone mass measurements.
Reconstructed 3D images of distal femurs were analyzed using a
Microviewer (GE Medical Systems). A fixed threshold was used to
separate the bone and marrow phases. The trabecular bone
mineral density (BMD), trabecular bone volume per tissue volume
(BV/TV), bone surface per bone volume (BS/BV), trabecular
thickness(Tb.Th),trabecularnumber(Tb.N),andtrabecularspacing
(Tb.Spac) in the distal femur were measured in a rectangular
cylinder within the metaphysis. Cortical surface area (CSA), cortical
area (CA), marrow area (MA), and cortical thickness (CT) were
measured in a rectangular circle in the diaphysis.
Statistics
One-way factorial analysis of variance (ANOVA) followed by
Tukey tests was used for the statistical analysis (Prism 5,
GraphPad Software, Inc., La Jolla, CA, USA). p values of less than
.05 were considered to be statistically significant. All statistical
data were presented as the mean SD.
Results
Expression of WISP-1 in human bone marrow cultures
during osteoblastic differentiation
TounderstandtheroleofWISP-1duringosteogenesisinvitro,we
first determined the mRNA expression profile of WISP1 in human
bone marrow stromal cells (hBMSCs) cultured under conditions
conducive for osteogenic differentiation by real-time PCR.
Expression of WISP1 was compared with the expression of the
early osteogenic marker alkaline phosphatase (ALP) and with
calcium accumulation, determined by alizarin red staining, a
functional assay of more mature osteoblastic differentiation
(Fig. 1). WISP1 displayed a temporal expression pattern that
followed a similar distribution to ALP (Fig. 1A, B), with peak levels
of WISP1 and ALP mRNA expression preceding the onset of
calcification (Fig. 1C).
WISP-1 enhances BMP-2 induced osteogenesis in vitro
and in vivo
To determine the effects of WISP-1 on in vitro osteogenesis, we
generated adenovirus that would express human WISP-1 under
the control of the CMV promoter (adWISP-1). We chose to use
adenovirus for WISP-1 overexpression studies based on previous
work from our laboratory that showed that nearly 100% gene
transfer could be achieved in hBMSCs by transduction with
Fig. 1. RelativeexpressionofalkalinephosphataseandWISP-1relativeto
alizarin red accumulation during the osteogenic differentiation of
hBMSCs. Cells were cultured with osteogenic induction medium, and
total RNA was collected at 0, 3, 7, 10, and 14 days, and the mRNA
expression levels of ALP (A) and WISP1 (B) were evaluated by real-time
PCR. The time points are the numbers of days after the cells reached
confluence. The expression of each gene was normalized to that of its
respective S29 ribosomal RNA. Data are reported as mean SE (n¼3).
   p<.001 versus day 0. (C) Alizarin red S staining in the cells whose ALP
and WISP1 mRNA expression patterns are shown in panel A.
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(50) First, adWISP-1 was transduced into cultures of
hBMSCs, and expression was analyzed by Western blotting. The
amountofWISP-1 proteinexpressionwasincreasedsubstantially
compared with cells transduced with control virus (adCMV) in a
dose-dependent manner (Supplemental Fig. S1).
To establish how WISP-1 could induce osteogenic differentia-
tion of hBMSCs, we tested the effect of WISP-1 overexpression
on BMP-2-induced osteogenic differentiation using adenovirus
encoding BMP-2 (adBMP-2). hBMSCs were transduced with
either adWISP-1 and adBMP-2 alone or in combination, and after
culture in osteogenic differentiation medium, cultures were
assayed for expression of osteogenic markers by real-time PCR.
After 7 days of culture transduction with adWISP-1 alone, there
was no significant effect on osteogenic marker expression.
However, adBMP-2-transduced cells had increased osteogenesis
and showed significantly higher levels of mRNA for ALP (Fig. 2A),
but not for the later osteogenic marker osteopontin (OPN)
(Fig. 2B). Cotransduction with adBMP-2 and adWISP-1 signifi-
cantlyenhancedALPmRNAlevelsoverandabovethatofadBMP-
2 alone and additionally increased expression of OPN (Fig. 2A, B).
We also tested the effect of WISP-1 overexpression on BMP-2-
induced calcium accumulation. As shown by others previously,
transductionofhBMSCswithadBMP-2significantlyincreasedthe
intensity of alizarin red staining (Fig. 2C, lower left, D, third bar),
which we could increase further by cotransduction with adWISP-
1 (Fig. 2C, lower right, D, last bar). When this experiment was
repeated using recombinant proteins, the combined application
of rhWISP-1 and rhBMP-2 also stimulated osteogenesis (Supple-
mental Fig. S2), but in our hands it was more variable in outcome
than adenovirus transduction. We believe this may be due, in
part, to lot variation in the BMP-2, WISP-1, or both. For this
reason, we performed the majority of experiments using the
adenoviral system. All our data so far support the concept
that WISP-1 acts to enhance BMP-2-mediated osteogenesis of
hBMSCs.
To determine whether WISP-1 potentiation of BMP-2-induced
osteogenic differentiation was mediated directly by enhancing
BMP-2 signaling, we examined the effect of WISP-1 on down-
stream signaling events. First, we analyzed the effect of WISP-1
on BMP-2-induced gene transcription using a BMP-responsive
luciferase reporter construct stably transfected into C2C12 cells
(C2C12-Bre-Luc).
(46) C2C12-Bre-Luc cells were transduced with
adWISP-1, adBMP-2, a combination of adWISP-1 and adBMP-2, or
a control adenovirus adCMV, and 5 days after transduction,
luciferase activity was measured. Luciferase activity was
increased 46-fold in adBMP-2-transduced cells compared with
cells infected with adCMV (Fig. 3A, bar 3). C2C12 cells transduced
with the combination of adBMP-2 and adWISP-1 had a 78-fold
increase in luciferase activity compared with adCMV-transduced
cells, WISP-1 thus increasing BMP-2-induced transcription
activation almost twofold (Fig. 3A, bar 4). We next dissected
the molecular mechanism involved in WISP-1 enhancing the
effect on BMP-2 by analyzing the effect of WISP-1 on BMP-2-
induced Smad phosphorylation after 48hours of transduction.
AdBMP-2 transduction increased relative levels of pSmad-1/5/8,
but no effect of adWISP-1 transduction was observed, similar to
our observations in osteogenic differentiation. However, trans-
duction withboth adBMP-2and adWISP-1enhancedSmad-1/5/8
phosphorylation over adBMP-2 alone (Fig. 3B) in a statistically
significant fashion (Fig. 3C), suggesting that WISP-1 potentiates
BMP-2 activity by increasing the level of Smad-1/5/8 activation.
These data indicate that WISP-1 enhances BMP-2 function
by increasing Smad-1/3/5 phosphorylation and subsequently
activating BMP-2-responsive gene transcription.
Toconfirmthatourinvitrofindingscouldbereplicatedinvivo,
we performed two different experiments that used either a gain
or loss of WISP-1 function strategy. First, in a gain-of-function
approach,hBMSCsweretransducedwithadWISP-1andadBMP-2
singly or in combination and then implanted under the skin of
immunocompromised mice. Four weeks after implantation, the
ectopic new bone that was formed by the cells was assessed by
histology. As predicted from our in vitro work, adBMP-2-
transduced cells generated more bone than cells that were
transduced with adCMV (Fig. 4A, B). Cells transduced with both
adBMP-2 and adWISP-1 had significantly greater bone formation
than those transduced with adBMP-2 alone (Fig. 4A, B),
confirming our earlier in vitro finding that showed that WISP-
1 can enhance the ability of BMP-2 to stimulate osteogenesis.
Fig. 2. WISP-1 enhances the effects of BMP-2-induced osteoblastic dif-
ferentiaion in vitro. Relative mRNA expression levels of ALP (A) and OPN
(B) measured by real-time RT-PCR 7 days after the transduction with
adWISP/adBMP-2. The expression of each gene was normalized relative
to S29 ribosomal RNA.
 p<.05;
   p<.001 versus adCMV-transduced
sample; and
###p<.001 versus adBMP-2-transduced sample. (C) hBMSCs
stained with alizarin red S to measure Ca
2þ deposition after transduction
with adWISP-1 and adBMP-2 separately or in combination when cultured
in osteogenic induction medium for 2 weeks. (D) Quantitative evaluation
of alizarin red S staining. Data are reported as mean SE (n¼3).
 p<.05;
   p<.001 versus the sample transduced with adCMV; and
#p<.05
versus the sample transduced with adBMP-2. AdWISP-1 alone had little
effect on hBMSC osteogenic potential but did enhance the effect of
adBMP-2 on ALP and OPN expression (A, B) and mineralization (C, D).
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WISP1 shRNAs packaged into lentivirus. We used lentivirus
because of its ability to integrate into host cells and thereby
maintain the WISP1 knockdown throughout the process of
osteogenic induction in vitro and in vivo. In this experiment, five
different shRNAs were first tested for their ability to knock down
WISP1 expression, and one candidate was chosen, B10, that
reduced WISP1 mRNA levels over 90% compared with controls
(Supplemental Fig. S3 and Fig. 5C). When tested in vivo using
the implant system, hBMSCs infected with WISP1 shRNA
lentivirus had dramatically reduced bone formation compared
with cells transduced with control lentivirus (Fig. 5A, B) 6 weeks
Fig. 3. EffectofWISP-1andBMP-2on reporter activationandinducedSmad-1/5/8 phosphorylation. (A) To testtheBMP-sensitiveId1promoteractivation,
C2C12 cells were transduced with adWISP-1 and adBMP-2 (1000 particles/cell) separately or in combination, and after 5 days, luciferase activity was
measured.
   p<.001 versus the sample tranduced with adCMV and
###p<.001 versus the sample transduced with adBMP-2. (B) Smad-1/5/8
phosphorylation was measured in hBMSCs transduced with adWISP-1 and adBMP-2 (5000 particles/cell) separately or in combination. After 48 hour,
total cell lysates were collected and resolved by gel electrophoresis and transferred to PVDF membrane and then were incubated with an antibody to
either phosphorylated Smad-1/5/8 (p-Smad-1/5/8) or total Smad-1. HSP90 served as an internal control. The experiment was repeated three times, and
relative levels of p-Smad/total Smad were plotted graphically in panel C. Data are reported as mean SE (n¼3).
 p<.05;
   p<.001 versus the sample
transduced with adCMV; and
#p<.05 versus the sample transduced with adBMP-2.
Fig. 4. Effects ofWISP-1andBMP-2on osteogenesis invivo. hBMSCsweretransducedwithcontrolCMVadenovirus(adCMV),adWISP-1,adBMP-2, or both
and then implanted under the skin of immunocompromised mice. Implants were harvested after 4 weeks and analyzed by histology. (A) Representative
sections from implants, with black arrows pointing to regions of ectopic bone formation. (B) Quantitation of the area of bone formed in four
random sections from implants shown in panel A.
 p<.05;
   p<.001 versus sample transduced with adCMV; and
###p<.05 versus sample transduced
with adBMP-2.
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to be due to a diminished ability of the WISP1 shRNA–infected
hBMSCs to undergo differentiation, judged by the reduction in
the expression of both early and late markers of osteogenesis,
ALP and OPN, respectively (Fig. 5D, E). We next used the shRNA
system to assess the dependence of BMP-2 function on WISP-1.
hBMSCs that had WISP-1 reduced by shRNA showed reduced
phosphorylation of p-Smad-1/5/8 in response to adBMP-2
(Fig 5F) and, further, had less osteogenic differentiation in
response to adBMP-2, judged by the expression of ALP mRNA
(Fig. 5). It is not clear why overexpression of WISP-1 by adWISP-1
transduction did not significantly affect osteogenesis, whereas
in the shRNA WISP1 knockdown experiment it was decreased
significantly, but we presume that factors such as gene
transfer mode (lenti versus adeno), timing, or other down-
stream elements are involved. In addition to that, it must
be noted that there was some variability in the osteogenic
response of exogenous recombinant BMP-2 depending on
the batch used (data not shown). Nevertheless, taken
together, these data indicate that the induction of osteogenesis
by BMP-2 is enhanced by and depends on the presence of
WISP-1.
Fig. 5. EffectofWISP1knockdownonosteogenesisinvivoandinvitro.(A)hBMSCswereinfectedwithlentivirusharboringcontrolshRNA(GFP)orshWISP-
1 and implanted ectopically to assess bone formation capacity in vivo when harvested at 6 weeks. Arrows point to sites of ectopic bone formed in the
implant. (B) Quantitation of the area of new bone formed in control lentivirus (GFP) compared with shWISP-1 lentivirus–infected hBMSCs.
   p<.001
versus GFP-infected cells. Relative expression levels of WISP1 mRNA (C), ALP mRNA (D), and OPN mRNA (E) in hBMSCs infected with lentivirus containing
shRNA to WISP1.
   p<.001 versus GFP. ( F) Relative levels of p-Smad and total Smad-1/5/8 in hBMSCs infected with GFP lentivirus controls and shWISP-1
lentiviruseitherwith or withouttreatment with recombinant humanBMP-2 (rhBMP-2).(G) Relativeexpressionof ALP mRNAin the samesamplesshown in
panel F.
  p<.01 versus GFP. WISP1 shRNA–infected cells showed diminished response to rhBMP compared with control cells.
200 Journal of Bone and Mineral Research ONO ET AL.WISP-1 directly binds to BMP-2 and can increase BMP-2
binding to hBMSCs
PreviousstudieshaveshownthatotherCCNfamilymemberscan
bindtoBMPs andregulate theirfunction.
(15,16) AnalysisofWISP-1
protein structure by our laboratory and others has indicated
a region in the CT domain with high homology to the BMP-2
antagonist noggin
(11) and another cysteine-rich region homo-
logoustochordinintheVWF-likedomain.
(13)Giventhis evidence
and our functional data indicating that WISP-1 can affect BMP-2
action,wespeculated that WISP-1 maybind toBMP-2 toregulate
its function. To test this, we used solid-phase binding and
coimmunoprecipation experiments. When increasing amounts
of WISP-1 were coated onto tissue culture plates and then
incubated with BMP-2, the amount of BMP-2 detected using
BMP-2-specific antibody increased proportionally to WISP-1
concentration (Fig. 6A). In the reverse, when increasing amounts
of BMP-2 were coated onto solid supports and were incubated
subsequently with WISP-1, we found that the amount of WISP-1
detected using antibodies to WISP-1 also increased proportion-
ally to the amount of BMP-2 bound to the plate (Fig. 6B). A
comparison of BMP-2 binding to other members of the CCN
family revealed that BMP-2 had greater binding affinity for WISP-
1 than for CTGF but lower than that for Nov (Supplemental
Fig. S4). To determine whether WISP-1 and BMP-2 could bind
directly to each other in cells, we next performed coimmuno-
precipiation experiments (co-IP) in which hBMSCs were
transduced with adWISP-1 and/or adBMP-2, and then 5 days
later, cell lysates were subjected to co-IP. The specificity of the
experiment was tested using both positive controls for WISP-1
and BMP-2 (IB: WISP-1; IB: BMP-2) and negative controls using
lysates immunoprecipiated with antibody to IgG (IP: IgG).
Western blot analysis for WISP-1 of cell lysates immunopreci-
pitated with a BMP-2 antibody revealed that the BMP-2
immunoprecipitate contained WISP-1 (Fig. 6C, bottom panel,
IP: BMP-2, IB: WISP-1), indicating an interaction between WISP-1
and BMP-2 under these conditions. Some BMP-2 was observed
immunoprecipitated in samples without prior adBMP-2 treat-
ment and was assumed to come from endogenous BMP-2
constituatively produced by the hBMSCs. WISP-1 and BMP-2 are
both secreted proteins, and thus interactions must take place
outside the cell. Therefore, we next tested whether WISP-1
overexpression could affect BMP-2 binding to hBMSCs. Cultures
transduced with increasing doses of adWISP-1 were incubated
Fig. 6. Interaction between WISP-1 and BMP-2. (A, B) Solid-phase binding assay for WISP-1 and BMP-2. Tissue culture wells were precoated with different
concentrations of either WISP-1 (A) or BMP-2 (B) (0.3, 1, and 3mg/mL) and incubated with BMP-2 (A) or WISP-1 (B), respectively, at 378C for 2hours. Total
binding of each protein was determined by measuring immunoreactivity toward the anti-BMP-2 antibody (A) or anti-WISP-1 antibody (B). Data are
reported as mean SE (n¼4).
 p<.05;
   p<.001 versus the sample treated with 0.3mg/mL of protein. (C) Immunoprecipitation using BMP-2 antibody.
hBMSCsweretransducedwithadWISP-1andadBMP-2separatelyorincombination,andafter3days,celllysateswerecollected.Immunoprecipitationwas
performedusingananti-BMP-2antibody,andtheamountofWISP-1‘‘pulleddown’’wasmeasuredusingananti-WISP-1antibody.(D)TheaffinityofBMP-2
forbindingtohBMSCstransducedwithadWISP-1.hBMSCsweretransducedwithadWISP-1inhBMSCs,and3 dayslater,thecellswerefixedandincubated
with BMP-2 for 2hours. The amount of BMP-2 bound to the cells was evaluated by measuring the amount of immunoreactivity using an anti-BMP-2
antibody. The relative amount of BMP-2 present was normalized to the levels of b-actin. Data are reported as mean SE (n¼4).
  p<.01;
   p<.001
versusthenontransducedsample.(E)LevelsofcellsurfaceassociatedWISP-1inhBMSCstransducedwithadWISP-1,andafter3days,theamountofWISP-1
was normalized to b-actin. Data are reported as mean SE (n¼4).
   p<.001 versus the nontransduced sample.
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against BMP-2. As a control, WISP-1 levels a were also assayed
using anti-WISP-1 antibody. Increasing amounts of BMP-2 were
detected paralleling increased transduction with adWISP-1
(Fig. 6D), and increased expression of WISP-1 with maximum
effects observed at 1000 PFU/cell (Fig. 6E). It is not clear why cells
having the highest levels of WISP-1 had slightly less BMP-2
bound, but we assume that this may be from yet to be identified
downstream effects on the treated cells. These data taken
together support the concept that WISP-1 can enhance BMP-2
function by facilitating its binding to the surface of hBMSCs and
induce downstream signaling and transcription of BMP-2-
sensitive genes, thereby enhancing BMP-2-induced osteogenic
differentiation.
Integrin a5b1 may regulate the functional relationship of
WISP-1 and BMP-2
Previous studies have indicated that the CCN family can act to
regulate the expression of integrins, and in turn, integrins can
serveasreceptorsforCCNfamilymemberssuchasCyr61.
(31,32,34–
38,51) We determined the effect of WISP-1 on the expression of
mRNA encoding a5, aV, b3, and b1, integrin subunits shown
previously to be regulated by CCN family members, in hBMSCs.
No effects on the expression level of aV, b3,o rb1 mRNA levels
were observed following adWISP-1 transduction (Fig. 7B–D).
However, we observed significant effects of adWISP-1 transduc-
tion on integrin a5 mRNA that was increased almost twofold
(Fig. 7A) compared with adCMV-transduced controls. These
increases in a5 mRNA levels were confirmed at the protein level
by Western blotting (Fig. 7E), indicating that overexpression of
WISP-1 selectively increases a5 mRNA and protein in hBMSCs.
To investigate the significance of WISP-1’s selective effect on
a5 subunit expression, we first tested the possibility that there is
a physical interaction between WISP-1 and the a5 subunit
by solid-phase binding assay and co-IP. Solid-phase binding
revealed that the amount of a5b1 detected depended on the
amount of WISP-1 protein present (Fig. 8A). Conversely, the
amount of bound WISP-1 detected was increased dose-
dependently by the amount of integrin a5b1 protein present
(Fig. 8B). This interaction was confirmed in vitro by co-IP of cells
transduced with adWISP-1 for 5 days, revealing that IP with
antibodies to a5b1 could pull down WISP-1 that was detected by
Western blot analysis (Fig. 8C). Finally, to determine if there is a
functional relationship between WISP-1, BMP-2, and integrin
a5b1, we performed an inhibition assay using a5b1-blocking
antibodies. In this experiment, hBMSCs were transduced with
adWISP-1 or adCMV control, and then BMP-2 binding was tested
in the presence or absence of blocking antibody to a5 or to the
control IgG. As shown in Fig. 8D, the amount of BMP-2 bound to
cells that overexpressed WISP-1 was inhibited by the addition of
antibodies to integrin a5. Treatment with IgG control antibody
did not diminish the binding of BMP-2 to WISP-1-overexpressing
cells, indicating that the effect was specific for the interaction
with a5. Cells treated with blocking antibodies to a5b1 had total
inhibition of osteogenesis judged by ALP mRNA expression
(Supplemental Fig. S5), and while revealing the importance of
a5b1 in ALP mRNA production, it precluded further testing of
WISP-1 in the differentiation process. Nevertheless, taken
together, these results suggest that WISP-1 potentially could
enhance BMP-2 binding to BMSCs through an interaction
involving integrin a5b1.
Pilot characterization of WISP1 transgenic mice
To further confirm that there are potential functions for WISP-1
during osteogenesis in vivo and to create an animal model for
future studies, a transgenic mouse line was generated that
expressed WISP-1 under the control of the 2.3-kb Col1Al
promoter, which directs expression to mineralized tissues
(Fig. 9A). At birth, no gross abnormalities were observed, and
normal Mendelian ratios were observed; moreover, the overall
Fig. 7. Effect of WISP-1 on the production of a5.( A–D) Relative expression levels of a5, aV, b3, and b1 mRNA in hBMSCs transduced with adWISP-1 or
adWISP-1for3days,asdeterminedbyreal-timePCR.Theexpressionofeachgenewasnormalizedtothelevelof S29ribosomalRNA.
   p<.001versusthe
sample transduced with adCMV. (E) Representative Western blot analysis of a5 protein in hBMSCs transduced with adWISP-1 for 3 days.
202 Journal of Bone and Mineral Research ONO ET AL.health of these transgenics (termed WISP1-Tg) appeared to be
good. However, we found that female transgenics could not give
birth, and therefore, the lines could be maintained only by
breeding male WISP1-Tg mice with wild-type female mice. Of the
six founders identified by Southern blot analysis, WISP1-Tg line 5
was chosen for detailed analysis. This line was shown to
significantly express the human mRNA transgene, judged by the
amount of RNA amplified from osteoprogenitor cells using
human-specific oligonucleotides for RT-PCR (Fig. 9B). Western
blotting of cell extracts from the same cells was performed using
an antibody (LF-187) generated from a conserved amino acid
sequence that recognizes both mouse and human WISP-1 and
found the level of expression of WISP-1 to be increased above
endogenous mouse WISP-1 levels in BMSCs from WISP1-Tg mice
compared with the wild-type mice (Fig. 9C).
We first analyzed the skeleton of transgenic mice by X-ray
analysis, revealing that the most significant effects of WISP-1
were observed in the long bones of the axial skeleton. X-ray of
extracted long bones from 3-month-old wild-type and WISP1-Tg
mice revealed that transgenic mice had denser bone than wild-
type mice, and this was effect was most pronounced in WISP1-Tg
females (Fig. 10A). mCT 3D reconstruction of femurs from 2-
month-old females confirmed our observations of increased
bonedensityand,further,indicatedthatthetrabecularbonewas
the most affected area (Fig. 10B, C). Finer analysis of the distal
femurs revealed that the bone mineral density (BMD; Supple-
mental Fig. S7D), bone volume/total volume (BV/TV; Fig. 10E),
and trabecular number (Tb.N; Fig 10H) were significantly higher,
and correspondingly, trabecular spacing (TB.Spac) was signifi-
cantly lower (Fig. 10I) in the WISP1-Tg mice than in the wild-type
mice. While the trabecular thickness (Tb.Th) and the bone
surface/bone volume (BS/BV) showed an increased and
decreased trend, respectively, in the WISP1-Tg mice compared
with the wild-type mice, they were not significantly different
Fig. 8. Interaction of WISP-1 with a5b1.( A, B) Solid-phase binding of WISP-1– integrin a5b1 interactions. Tissue culture plates were coated with different
concentrations of WISP-1 (A) or integrin a5b1 (B) (0.3, 1, and 3mg/mL) and were incubated with integrin a5b1 (A) or WISP-1 (B), respectively, at 378C for
2hours.Theamountofbindingofeachproteinwasdeterminedby measuringimmunoreactivitytowardtheanti-integrin a5b1 antibody(A)or anti-WISP-1
antibody(B).Dataarereportedasmean SE(n¼4).
 p<.05versusthesampletreatedwith0.3mg/mLofprotein.(C)WesternblottingshowingthatWISP-
1 binds to integrin a5b1 using immunoprecipitation with anti-integrin a5b1 antibody. hBMSCs were transduced with adWISP-1 (5000 particles/cell), and
3 days later, the cell lysates were collected. Then immunoprecipitation and Western blotting were performed with anti-integrin a5b1 antibody and anti-
WISP-1 antibody, respectively. (D) Inhibition assay using anti-integrin a5b1 antibody. hBMSCs, were preincubated with or without anti-integrin a5b1
antibody (10mg/mL) or IgG antibody (10mg/mL) for 1 hour, and then cells were transduced with adWISP-1 (5000 particles/cell). Three days after
transduction,thecellswerefixedandincubatedwithBMP-2for2hours.BMP-2
þcellsweredetectedbymeasuringimmunoreactivitytowardtheanti-BMP-
2 antibody. The graph shows the quantitation of these data normalized to b-actin. Data are reported as mean SE (n¼4).
 p<.05;
   p<.001 versus
nontreatment in the sample transduced with adCMV;
###p<.001 versus treatment with anti-integrin a5b1 antibody in the sample transduced with
adWISP-1.
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area (MA; Fig. 10L) also were increased in the WISP1-Tg mice
compared with the wild-type mice, but no significant differences
were observed cortical area (CA; Fig. 10K) or in cortical thickness
(CT; Fig. 10M). It must be clearly noted that that these data are
reamed from a single transgenic line and will need to be
confirmed with additional lines of mice or by creating WISP1
knockout mice. With this caveat in mind, these data provide
another line of evidence to support the idea that WISP-1 has a
positive effect on bone formation in vivo (Fig. 5A).
Discussion
The goal of this study was to determine the role of WISP-1 in
osteogenesis and to further understand its mechanism of action.
The results presented in this article indicate that WISP-1 can act
to induce osteogensis by enhancing the ability of BMP-2 to
induce osteoblastic differentiation of osteoprogenitor cellsinthe
bone marrow. The molecular basis of the cooperative action of
WISP-1 and BMP-2 appears to work through an interaction of
integrin a5b1 at the cell surface of BMSCs. Pilot studies using one
line oftransgenic mice further indicate that WISP-1 hasa positive
influence on bone formation in vivo.
Our previous work indicated that WISP-1 might act coopera-
tively with members of the TGF-b superfamily to regulate
osteoblast function. BMPs aremembers ofthe TGF-bsuperfamily
that can regulate numerous cell activities, including differentia-
tion, proliferation, and apoptosis.
(42,43) As their name implies,
they play important roles in regulating the development and
maintenance of skeletal tissues.
(52,53) During osteogenesis, cells
express a series of proteins that are characteristic of the
differentiation process and include the production of Runx-2,
alkaline phosphatase, bone sialoprotein (BSP), and osteocalcin
(Ocn).
(54) This osteogenic process can be regulated by several
members of the BMP family, including BMP-2, BMP-4, and BMP-
7.
(42,43) During later stages of differentiation, antagonists of BMP
such as noggin and chordin have important functions such that
osteogenesis ultimately is controlled by a fine balance between
the levels of BMPs and their antagonists. The expression of WISP-
1 in preosteogenic cells is quite distinct from other CCN proteins
that are more prominently associated with cartilage develop-
ment at sites of secondary ossification.
(55) This observation
indicates that the function of CCN2 and CCN3 in bone might be
distinct from CCN4/WISP-1. Evidence to support this notion
comes from the fact that mice that overexpress CCN2/CTGF or
CCN3/Nov in bone have an osteopenic phenotype.
(15,16) In
contrast, we show here that overexpression of WISP-1 enhances
BMP-2-induced osteogenesis. CCN2, CCN3, and CCN4 all have
been shown bind to BMP-2. For CCN2/CTGF and CCN3/Nov, this
binding appears to inhibit BMP action,
(39,56) whereas for CCN4/
WISP-1, it appears to enhance it. Thus, despite the apparent
sequence similarities among different members of the CCN
family, it seems that they can serve as BMP antagonists or
agonists depending on the CCN type. This differential action of
individual CCN members could be due to their unique temporal-
spatial patterns of expression, where functional consequences
could be cell-, tissue-, or even age-dependent.
Since there are no known receptors for WISP-1, to further
understand the molecular mechanism involved in WISP-1
potentiation of BMP-2 action, we investigated the possibility
that WISP-1 may have an impact on pathways that can crosstalk
with BMP signaling. We finally focused our attention on the
integrins after examination of the ERK, p38, or JNK signaling
pathways; other pathways known to converge on BMP-2
signaling were found not to be differentially regulated by the
combined application of WISP-1 and BMP-2 (not shown).
Integrins have been identified as functional receptors for some
members of the CCN family, including CCN1/Cyr61 and CCN2/
CTGF.
(12,33,36,57–62) In some cases, the CCN proteins interacted
with other extracellular matrix proteins such as fibronectin and,
in so doing, play important roles in regulating cell adhesion and
migration.
(36,57–59) Using cells deficient in CCN2, Nishida and
colleagues
(63) found that the expression level of integrin a5b1
was downregulated. On the other hand, the expression of a5b1
was increased by adding CCN2 to chondrocytes. Antibody
blocking experiments have shown that CCN2 binding to
Fig. 9. TheexpressionofhWISP-1intransgenicmicedesignedtoexpress
hWISP-1 in bone. (A) A 1.3-kb DNA fragment coding for human WISP-1
was cloned downstream of a 2.4-Kb DNA containing the Col1A1 bone-
specific promoter (2.3-kb promoter plus 0.1-kb exon 1) and was used to
make transgenic mice. (B) mBMSCs were collected from WISP1-Tg and
wild-type mice and culturedwith osteogenic induction medium for up to
4 weeks after confluence. The relative expression levels of human WISP1
mRNA were determined in mBMSCs derived from wild-type (left)o r
WISP1-Tg (right) mice. In order to detect human WISP1 and mouse WISP1,
RT-PCR was performed using human WISP-1 or mouse-specific primers,
respectively (Table 1). RT-PCR of mRNA encoding Gapdh served as an
internal control. (C) To analyze the relative levels of WISP-1 protein, a
Western blot was performed using anti-WISP-1 antibody (upper panel),
where HSP90 served as an internal control (lower panel). The antibody,
LF-187, crossreacted with mouse WISP-1 but showed higher total levels
ofWISP-1(humanplusmouse)intheWISP1-Tgcellsastheybecamemore
osteogenic.
204 Journal of Bone and Mineral Research ONO ET AL.Fig. 10. Bone phenotype of the WISP1-Tg mice. (A) X-ray images of the femurs from 8-week-old WISP1-Tg and wild-type mice revealing increased density
ofbone,depictedbyincreasedX-rayintensity.(B)mCTimagesofofwild-typeandWISP1-Tgmice,confirmingincreasedbonedensity,asshowngraphically
by 2D images of sagittal sections of femurs from 8-week-old wild-type and WISP1-Tg mice. (C) 3D rendering of the trabecular bone shown. (D) Trabecular
bone mineral density (BMD), (E) trabecular bone volume per tissue volume (BV/TV), ( F) bone surface per bone volume (BS/BV), (G) trabecular thickness
(Tb.Th), (H) trabecular number (Tb.N), and (I) trabecular spacing (Tb.S), (J) cross-sectional area (CSA, mm
2), (K) cortical area (CA, mm
2), (L) medullary area
(MA, mm
2), (M) cortical thickness (mm). All measurements were obtained either from an elliptical cylinder within the metaphases or by imaging a cross-
sectional area in the midshaft region of the femur. Data are reported as mean SE (n¼6).
 p<.05;
  p<.01 versus wild-type sample.
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(36) A number
of studies also have implicated integrins in the activation of
signaling via TGF-b superfamily members, and cells lacking in
a5b1 integrin completely lack the ability to signal via TGF-b1.
(64)
These studies led us to speculate that integrins also could be
involved in the BMP-enhancing functions that we uncovered for
WISP-1 using cultured hBMSCs. Our experiments indicate that
overexpression of WISP-1 increases the expression of a5 mRNA
and protein in BMSCs. The functional consequence of the
increased a5 was further defined by experiments showing direct
protein-protein interactions between WISP-1 and integrin a5b1.
The essential role of a5 in WISP-1 enhancement of BMP-2 cell
binding was revealed using blocking antibodies to this integrin
subunit. Support of the importance of a5 in priming hBMSC
toward osteoblast differentiation and osteogenesis has been
reported recently
(65); however, it is conceivable that there are
additional associating factors that could further regulate the
WISP-1/BMP-2/a5 complex, but this still remains to be
determined. It also must be cautioned that the additional
experiments are needed to definitively prove the involvement of
a5 in WISP-1/BMP-2-induced osteogenesis. It is also possible that
receptors such as LRP5/6 could be involved in WISP-1 function in
bone in a way that is similar to what has been reported
previously for CCN2/CTGF.
(66,67) Sclerostin is an essential
regulator of bone mass that has been reported to act on both
LRP5/6 and BMP-2, and humans with inactivating mutations in
sclerostin/SOST develop van Buchem disease, which is char-
acterized by significantly increased bone mass.
(8,68) Interestingly,
sclerostin bears significant homology with the BMP antagonist
noggin
(69) and is also known act on BMP signaling as well as Wnt
signaling, albeit to a significantly lesser extent.
(70–72)
Recent reports have suggested there is a relationship between
WISP-1 and skeletal disease. For example, mutations in the
related CCN6/WISP3 have been found to be the genetic basis the
autosomal recessive skeletal disorder called progressive pseu-
dorheumatoid dyplasia (PPD).
(73) A single-nucleotide polymorph-
ism (SNP) inthe WISP1 genehas been identified that hasa strong
association with the severity of spinal osteoarthritis (OA) in a
population of postmenopausal Japanese women.
(74) Recently,
Blom and colleagues found that WISP-1 was highly increased in
the human OA and in the synovium and cartilage of mice with
experimentally induced OA.
(9) With regard to this latter study,
it is interesting to speculate that one reason WISP-1 might be
upregulated during OA is the increased bone turnover that can
occur in the subchondral bone in OA diseased tissue.
(75) Our
finding that WISP-1 can enhance BMP actions further suggests
that WISP-1 could contribute functionally to the bone changes
noted in the progression of OA.
(76) It is not clear at this time
which part of WISP-1 binds to BMP, but it is reasonable to
speculatethatit couldbethechordin-like domainknowntobind
BMP in other CCN family members and in some cases even
having enhancing effects.
(51)
Our finding that WISP-1 enhances the ability of BMP-2 to
stimulate osteogenesis could have important future applications
for improving BMP-2 function in bone healing. Initial studies on
the use of BMPs for regenerative medicine were extremely
promising when used in animals, but when tested in human
applications, they proved to be suboptimal and required
relatively large doses of the growth factor to be effective (see
refs.
(44) and
(52) for excellent reviews of the history and use of
BMPs for orthopedic trauma surgery). In order to improve the
performance of BMPs, several investigators have examined the
use of multiple BMPs and combinatorial gene/protein therapy.
These studiessuggest thatcombinationsofBMP-2and-7
(77,78)or
intermittent parathyroid hormone (PTH) therapy
(79) can improve
the efficacyofBMPinrepairingbonetissueduringfracture repair
or to improve healing after craniofacial surgery. Potentially,
WISP-1 could be used to enhance BMP-2 function in clinical
applications requiring the stimulation of osteogenesis.
In conclusion, our studies show that WISP-1 can enhance the
effects of BMP signaling and may work through an interaction
with a5b1 and that WISP-1 can have an anabolic effect on bone
mass in vivo when expressed in bone cells. It is possible that
multiple other cell types could be affected by WISP-1, including
osteoclasts, which are known to have an intimate relationship
with osteoprogenitor cells where WISP-1 is expressed. Future
investigations will be designed to identify the precise structural
domains in WISP-1 as well as additional accessory factors within
the extracellular matrix of bone that may modulate WISP-1
function to control skeletal maintenance with aging.
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